{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:20:42Z","timestamp":1768936842963,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11096-020-01190-2","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T17:03:14Z","timestamp":1604336594000},"page":"878-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman"],"prefix":"10.1007","volume":"43","author":[{"given":"Diana Arandi","family":"Hanbali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khamis Al","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Al","family":"Za\u2019abi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-4230","authenticated-orcid":false,"given":"Ibrahim","family":"Al-Zakwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"1190_CR1","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","volume":"63","author":"AP Ambrosy","year":"2014","unstructured":"Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123\u201333.","journal-title":"J Am Coll Cardiol"},{"key":"1190_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ejhf.549","volume":"18","author":"N Farr\u00e9","year":"2016","unstructured":"Farr\u00e9 N, Vela E, Cl\u00e8ries M, Bustins M, Cainzos-Achirica M, Enjuanes C, et al. Medical resource use and expenditure in patients with chronic heart failure: a population-based analysis of 88 195 patients. Eur J Heart Fail. 2016;18:1132\u201340.","journal-title":"Eur J Heart Fail"},{"key":"1190_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1190_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","volume":"71","author":"CW Yancy","year":"2018","unstructured":"Yancy CW, Januzzi JL Jr, Allen LA, Butler J, Davis LL, Fonarow GC, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;71:201\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"1190_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cjca.2017.08.022","volume":"33","author":"JA Ezekowitz","year":"2017","unstructured":"Ezekowitz JA, O\u2019Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive update of the Canadian cardiovascular society guide-lines for the management of heart failure. Can J Cardiol. 2017;33:1342\u2013433.","journal-title":"Can J Cardiol"},{"key":"1190_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"1190_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455\u201362.","journal-title":"Eur Heart J"},{"key":"1190_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"1190_CR9","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","volume":"19","author":"AS Koh","year":"2017","unstructured":"Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624\u201334.","journal-title":"Eur J Heart Fail"},{"key":"1190_CR10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ejhf.807","volume":"19","author":"K Tsuji","year":"2017","unstructured":"Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017;19:1258\u201369.","journal-title":"Eur J Heart Fail"},{"key":"1190_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jcma.2017.04.011","volume":"80","author":"HY Chang","year":"2017","unstructured":"Chang HY, Wang CC, Wei J, Chang CY, Chuang YC, Huang CL, et al. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: results from TSOC-HFrEF registry. J Chin Med Assoc. 2017;80:750\u20137.","journal-title":"J Chin Med Assoc"},{"key":"1190_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/0003319720905742","volume":"71","author":"M Zubaid","year":"2020","unstructured":"Zubaid M, Rashed W, Ridha M, Bazargani N, Hamad A, Banna RA, et al. Implementation of guideline-recommended therapies for patients with heart failure and reduced ejection fraction: a regional Arab middle east experience. Angiology. 2020;71:431\u20137.","journal-title":"Angiology"},{"key":"1190_CR13","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.amjcard.2011.02.322","volume":"107","author":"MJ Krantz","year":"2011","unstructured":"Krantz MJ, Ambardekar AV, Kaltenbach L, Hernandez AF, Heidenreich PA, Fonarow GC. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from get with the guidelines-heart failure). Am J Cardiol. 2011;107:1818\u201323.","journal-title":"Am J Cardiol"},{"key":"1190_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstr\u00f6m U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European society of cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry. Eur J Heart Fail. 2013;15:1173\u201384.","journal-title":"Eur J Heart Fail"},{"key":"1190_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/eurjhf\/hft011","volume":"15","author":"A Gjesing","year":"2013","unstructured":"Gjesing A, Schou M, Torp-Pedersen C, Dahlstr\u00f6m U, Filippatos G, Ponikowski P, et al. Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. Eur J Heart Fail. 2013;15:671\u20138.","journal-title":"Eur J Heart Fail"},{"key":"1190_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.510","volume":"18","author":"M Komajda","year":"2016","unstructured":"Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18:514\u201322.","journal-title":"Eur J Heart Fail"},{"key":"1190_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1190_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/ehf2.12454","volume":"6","author":"MJ Diamant","year":"2019","unstructured":"Diamant MJ, Virani SA, MacKenzie WJ, Ignaszewski A, Toma M, Hawkins NM. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure. ESC Heart Fail. 2019;6:774\u201383.","journal-title":"ESC Heart Fail"},{"key":"1190_CR19","first-page":"1","volume":"22","author":"K Balakumaran","year":"2018","unstructured":"Balakumaran K, Patil A, Marsh S, Ingrassia J, Kuo CL, Jacoby DL, et al. Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. Int J Cardiol Heart Vasc. 2018;22:1\u20135.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1190_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","volume":"7","author":"HPR Brunner-La","year":"2019","unstructured":"Brunner-La HPR, Linssen GC, Smeele FJ, Ingrassia J, Kuo CL, Jacoby DL, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry. JACC Heart Fail. 2019;7:13\u201321.","journal-title":"JACC Heart Fail"},{"key":"1190_CR21","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","volume":"6","author":"TK Teng","year":"2018","unstructured":"Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6:e1008\u201318.","journal-title":"Lancet Glob Health"},{"key":"1190_CR22","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883\u201390.","journal-title":"Eur Heart J"},{"key":"1190_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ahj.2017.04.010","volume":"189","author":"AD DeVore","year":"2017","unstructured":"DeVore AD, Thomas L, Albert NM, Butler J, Hernandez AF, Paterson JH, et al. Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry. Am Heart J. 2017;189:177\u201383.","journal-title":"Am Heart J"},{"key":"1190_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","volume":"5","author":"N Luo","year":"2017","unstructured":"Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, et al. Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: in-sights from get with the guidelines-heart failure (GWTG-HF). JACC Heart Fail. 2017;5:305\u20139.","journal-title":"JACC Heart Fail"},{"key":"1190_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/CIRCOUTCOMES.109.879478","volume":"3","author":"PN Peterson","year":"2010","unstructured":"Peterson PN, Rumsfeld JS, Liang L, Hernandez AF, Peterson ED, Fonarow GC, et al. Treatment and risk in heart failure: gaps in evidence or quality? Circ Cardiovasc Qual Outcomes. 2010;3:309\u201315.","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01190-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01190-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01190-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:24:43Z","timestamp":1628537083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01190-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01190-2","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was a thesis project for an M.Sc student (Diana Arandi Hanbali, first author) and was not funded.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}